<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591019</url>
  </required_header>
  <id_info>
    <org_study_id># 65171</org_study_id>
    <nct_id>NCT00591019</nct_id>
  </id_info>
  <brief_title>Use of Modafinil in the Treatment of Tinnitus</brief_title>
  <official_title>Use of Modafinil in the Treatment of Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study on the effects of the FDA approved drug Modafinil upon attention problems associated&#xD;
      with tinnitus. This is considered to be a safe drug with few side effects. Each subject will&#xD;
      be asked to participate in 3 sessions each lasting approximately 1 hour in which cognitive&#xD;
      testing and recordings will be taken. The study involves each subject taking a 2- week supply&#xD;
      of Modafinil and a 2- week supply of placebo. We hypothesize inattention related to&#xD;
      thalamocortical dysrhythmia found in tinnitus can be reduced by Modafinil thus improving&#xD;
      vigilance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modafinil, a drug primarily used in the treatment for narcolepsy, is also being using in&#xD;
      treating attention problems found in Attention Deficit Hyperactive Disorder (ADHD). This&#xD;
      study will investigate the efficacy of Modafinil upon attention deficits found in tinnitus&#xD;
      patients by assessing pre-attentional and attentional processes (e.g., the amplitude of&#xD;
      auditory evoked responses and simple reaction time).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to lack of change in primary and secondary outcome measures.&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The P50 Amplitude (i.e. Evoked Auditory Response Potential Recorded in Millivolts 50 Milliseconds After Sound Onset).</measure>
    <time_frame>5 weeks</time_frame>
    <description>P50 is an auditory evoked response potential sensitive to states of arousal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Simple Reaction Time (Attention)for Baseline, Modafinil and Placebo Arms.</measure>
    <time_frame>5 weeks</time_frame>
    <description>Simple reaction time to an auditory signal is a measure of attention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>modafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>200 mg/day, morning dose</description>
    <arm_group_label>modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill once per day in the morning.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The diagnosis of tinnitus should be established by subject through exam and history&#xD;
             performed by study physician in Ear, Nose and Throat (ENT) clinic.&#xD;
&#xD;
          -  Subjects will be age 20 or older.&#xD;
&#xD;
          -  Subjects should have tinnitus symptoms severe enough to seek medical attention.&#xD;
&#xD;
          -  Subjects will have been seen in the Hearing and Balance Center at University of&#xD;
             Arkansas for Medical Sciences (UAMS).&#xD;
&#xD;
          -  Subjects will have had an audiogram.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test at screening and&#xD;
             before being prescribed the study drug.&#xD;
&#xD;
          -  Peripheral neuropathy.&#xD;
&#xD;
          -  Hematologic (minimal values) at screening Absolute neutrophil count &gt; 1,500 mm^3&#xD;
             Hemoglobin &gt; 8.0 g/dl Platelet count &gt; 100,000 mm^3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Disease-Specific Concerns&#xD;
&#xD;
          -  Subjects who have locally advanced breast cancer with skin ulceration will be excluded&#xD;
             from this study due to the risk of worsening ulcers and healing difficulties&#xD;
&#xD;
          -  Stage IV breast cancer&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
        General Medical Concerns&#xD;
&#xD;
          -  Subjects with Echo Cardiogram performance status 2, 3, and 4 are not eligible for this&#xD;
             study&#xD;
&#xD;
          -  Allergy to any component of the treatment regimen&#xD;
&#xD;
          -  Women who are breast feeding&#xD;
&#xD;
          -  Pregnancy or refusal to use effective contraception while participating in this study&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Subjects with secondary malignancy other than superficial skin cancer (squamous cell&#xD;
             carcinoma and basal cell carcinoma of the skin) should be excluded&#xD;
&#xD;
        Bevacizumab-Specific Concerns&#xD;
&#xD;
          -  Current, recent (within 4 weeks of the first infusion of this study), or planned&#xD;
             participation in an experimental drug study&#xD;
&#xD;
          -  Blood pressure of &gt; 150/100 mmHg. Essential hypertension well controlled with anti&#xD;
             hypertensive is not an exclusion criterion&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see&#xD;
             Appendix D)&#xD;
&#xD;
          -  History of myocardial infarction within 6 months&#xD;
&#xD;
          -  History of stroke within 6 months&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Presence of central nervous system or brain metastases&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 0, anticipation of need for major surgical procedure during the course of&#xD;
             the study&#xD;
&#xD;
          -  Minor surgical procedures such as fine needle aspirations or core biopsies within 7&#xD;
             days prior to Day 0&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or lactating&#xD;
&#xD;
          -  Urine protein: creatinine ratio &gt;1.0 at screening&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to Day 0&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Dornhoffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>February 28, 2011</results_first_submitted>
  <results_first_submitted_qc>April 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2011</results_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P50, Psychomotor Vigilance Test (PVT), Arousal, Reaction Time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from treatment clinic, seeking treatment for tinnitus.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Baseline, Modafinil 200 mg/Day, Placebo</title>
          <description>Subjects are tested at baseline, then after Modafinil (200mg/day, a.m. administration) for 14 days, then after placebo (for 14 days).</description>
        </group>
        <group group_id="P2">
          <title>Baseline, Placebo, Modafinil 200 mg/Day</title>
          <description>Subjects are tested after baseline, then after taking a sugar pill once per day in the morning for 14 days, and then after taking modafinil 200 mg/day for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 1 (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">One subject dropped out after baseline</participants>
                <participants group_id="P2" count="3">One subject dropped out after baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intevention 2 (14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Subjects were tested at baseline, then entered either the modafinil or placebo condtion and then the remaining condition.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The P50 Amplitude (i.e. Evoked Auditory Response Potential Recorded in Millivolts 50 Milliseconds After Sound Onset).</title>
        <description>P50 is an auditory evoked response potential sensitive to states of arousal.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Testing.</title>
            <description>Establish baseline levels of performance</description>
          </group>
          <group group_id="O2">
            <title>Modafinil</title>
            <description>Subjects are tested after taking Modafinil (200mg/day, a.m. administration) for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects are tested after taking a sugar pill once per day in the morning for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The P50 Amplitude (i.e. Evoked Auditory Response Potential Recorded in Millivolts 50 Milliseconds After Sound Onset).</title>
          <description>P50 is an auditory evoked response potential sensitive to states of arousal.</description>
          <units>milli volts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread=".15"/>
                    <measurement group_id="O2" value="1.47" spread=".28"/>
                    <measurement group_id="O3" value="1.23" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simple Reaction Time (Attention)for Baseline, Modafinil and Placebo Arms.</title>
        <description>Simple reaction time to an auditory signal is a measure of attention.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Testing.</title>
            <description>Establish baseline levels of performance</description>
          </group>
          <group group_id="O2">
            <title>Modafinil</title>
            <description>Subjects are tested after taking Modafinil (200mg/day, a.m. administration) for 14 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subjects are tested after taking a sugar pill once per day in the morning for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Simple Reaction Time (Attention)for Baseline, Modafinil and Placebo Arms.</title>
          <description>Simple reaction time to an auditory signal is a measure of attention.</description>
          <units>milli seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269.80" spread="12.64"/>
                    <measurement group_id="O2" value="268.12" spread="14.41"/>
                    <measurement group_id="O3" value="247.11" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baseline Testing.</title>
          <description>Establish baseline levels of performance</description>
        </group>
        <group group_id="E2">
          <title>Modafinil</title>
          <description>Subjects are tested after taking Modafinil (200mg/day, a.m. administration) for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Subjects are tested after taking a sugar pill once per day in the morning for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to lack of change in primary and secondary outcome measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr John Dornhoffer</name_or_title>
      <organization>University of Arkansas for Medical Sciences (UAMS)</organization>
      <phone>501 686-5140</phone>
      <email>dornhofferjohnl@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

